🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Wondering why different nonsense mutations are corrected with different efficacy? The short answer is: translation velocity determines the suppressor tRNAs efficacy. More details👇🏻in our new publication ⁦⁦⁦Nature Communications⁩.Kudos to the whole team! nature.com/articles/s4146…

Join Tevard's Co-Founder and CEO Daniel Fischer at the Next Generation #RNA Therapeutics Summit in Boston as he discusses advances in #tRNA therapeutics for the treatment of genetic diseases.

Join Tevard's Co-Founder and CEO Daniel Fischer at the 17h Nano-Bio Symposium at Johns Hopkins as he participates in a panel discussion on Unlocking the Promise of #mRNA Medicines. #mRNA #tRNA #genetherapy

Join Tevard co-founders Harvey Lodish and Warren Lammert at the Global Rare Diseases Research Symposium in Shanghai, China to hear about our novel tRNA-based therapies. #rare #rarediseases #trna bit.ly/3yplCQi

Join Greg Robinson, Tevard's Chief Scientific Officer, at Cure Duchenne's Futures conference in Orlando as he discusses our work in developing novel tRNA-based therapies to treat Duchenne Muscular Dystrophy. #CureDuchenne #CureDuchenneFutures #tRNA #RareDiseas

We welcome industry veteran and RNA therapeutics expert John Maraganore, founding CEO of Alnylam, as Strategic Advisor and Board Observer. tevard.reportablenews.com/pr/john-maraga…

We're thrilled to move our HQ to Lilly Gateway Labs! Being selected to join Former Account of Eli Lilly and Company's innovation hub demonstrates the ability of our tRNA platform & potential of our programs in neurological, cardiac, and muscular disorders. Learn more: bit.ly/3SM1L5h #biotech

We're looking forward to the upcoming RNA Leaders USA Congress. Tevard CEO, Daniel Fisher, will give a presentation on our work to pioneer novel tRNA therapeutics and how our platform is enabling us to advance our pipeline. See the full agenda: bit.ly/3T9n295 #RNALeaders

At Tevard, we're devoted to improving the lives of people with severe genetic diseases like Duchenne muscular dystrophy (DMD). In honor of #WorldDuchenneAwarenessDay, learn more about DMD, and see how you can help raise awareness: bit.ly/3qh209B #WDAD24

We look forward to attending the Epilepsy Foundation of America Pipeline Conference to discuss the latest advancements in epilepsy treatments. If you're attending, catch our presentation on September 26 to learn more about our pioneering approach to develop tRNA therapeutics. #biotechnology

November is National Epilepsy Awareness Month! At Tevard, we're advancing therapies to cure genetic diseases, including epilepsy. Visit Epilepsy Foundation of America to learn about this year's theme - #ShareYourPurplePower and get involved: bit.ly/3UNhvWE #NEAM2024

Tevard is excited to commemorate Rare Disease Month with our fellow Lilly Gateway Labs community members this February! #RareDiseaseDay

Data at #ASGCT2025 showed suppressor tRNA therapy restored full-length dystrophin up to 27% in a #Duchenne (DMD) model. Durable and potent efficacy and improved behavioral outcomes without observable side effects across multiple muscles demonstrated. rb.gy/pz9gdf

Director of Research at @TevardBio, Peter Eimon will present at #CureDuchenne #2025FUTURES: data show up to 27% restoration of full-length dystrophin in a #DMD model, sustained for 12+ weeks with no adverse effects.

Excited to welcome Dr. Elisabeth Gardiner to the team as our new Chief Scientific Officer! Her expertise will be instrumental as we advance our lead program targeting TTN-related dilated cardiomyopathy (data expected soon!) and we expand our pipeline. rb.gy/lx3ay5

Pleased to present at mRNA Horizons: Investor Summit for Breakthroughs in Medicine on June 24 (10AM–5PM), hosted by Alliance for mRNA Medicines with astr partners + Brown Rudnick. Exciting day ahead with top innovators + investors in mRNA! #mRNAHorizons #biotech #lifesciences

Today is International #DravetSyndromeAwarenessDay A rare form of epilepsy, Dravet begins in infancy and impacts individuals for life. Our founders have deep personal ties to Dravet; in fact, our company is named for the mission of reversing Dravet (spelled backward is Tevard).

🧬Exciting data from the 2025 RNA Therapeutics conference! Tevard's Julien Oury, PhD shared compelling preclinical results showing suppressor tRNAs restored up to 34% dystrophin & improved muscle function in a DMD model. 🔬 No off-target effects observed.

👏 Thanks to ed silverman and STAT for highlighting our new CSO, Elisabeth Gardiner. We’re excited to have her join us to advance our tRNA platform to cure rare genetic diseases. 🚶‍♀️ Learn more about Elisabeth here: tinyurl.com/ytk4w98w #tRNA #RareDisease